Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

NCT01241292 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: BMS-901608 (Elotuzumab) 10 mg
BIOLOGICAL: BMS-901608 (Elotuzumab) 20 mg

Sponsor

Bristol-Myers Squibb